[8-K] Centrus Energy Corp. Reports Material Event
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. and Steven A. Cohen jointly filed a Schedule 13G disclosing passive ownership of 588,632 shares of Avalo Therapeutics, Inc. (AVTX) as of 4 Aug 2025. The position represents 5.4 % of the company鈥檚 outstanding common stock, meeting the threshold that requires beneficial-ownership disclosure under Section 13(d) of the Exchange Act.
The shares are held by Point72 Associates, an investment fund managed by Point72 Asset Management. All three reporting persons share voting and dispositive power; none claim sole authority. The filing states the stake is not intended to influence control of Avalo and is classified as a passive investment (Rule 13d-1(c)). Signatures were executed by authorized person Jason M. Colombo on 5 Aug 2025. An Exhibit 99.1 Joint Filing Agreement is included.
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. e Steven A. Cohen hanno presentato congiuntamente un Schedule 13G, rivelando una partecipazione passiva di 588.632 azioni di Avalo Therapeutics, Inc. (AVTX) al 4 agosto 2025. La posizione rappresenta il 5,4% del capitale sociale ordinario in circolazione, superando la soglia che richiede la divulgazione del possesso effettivo ai sensi della Sezione 13(d) dell'Exchange Act.
Le azioni sono detenute da Point72 Associates, un fondo di investimento gestito da Point72 Asset Management. Tutti e tre i soggetti segnalanti condividono il potere di voto e dispositivi; nessuno rivendica autorit脿 esclusiva. La dichiarazione afferma che la partecipazione non 猫 destinata a influenzare il controllo di Avalo ed 猫 classificata come investimento passivo (Regola 13d-1(c)). Le firme sono state apposte dall'autorizzato Jason M. Colombo il 5 agosto 2025. 脠 incluso un Exhibit 99.1, Accordo di Deposito Congiunto.
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. y Steven A. Cohen presentaron conjuntamente un Schedule 13G revelando una propiedad pasiva de 588,632 acciones de Avalo Therapeutics, Inc. (AVTX) al 4 de agosto de 2025. La posici贸n representa el 5.4 % del capital social com煤n en circulaci贸n, cumpliendo con el umbral que exige la divulgaci贸n de propiedad beneficiaria bajo la Secci贸n 13(d) de la Exchange Act.
Las acciones son mantenidas por Point72 Associates, un fondo de inversi贸n gestionado por Point72 Asset Management. Las tres personas que reportan comparten el poder de voto y dispositivos; ninguna reclama autoridad exclusiva. La presentaci贸n indica que la participaci贸n no est谩 destinada a influir en el control de Avalo y se clasifica como una inversi贸n pasiva (Regla 13d-1(c)). Las firmas fueron ejecutadas por la persona autorizada Jason M. Colombo el 5 de agosto de 2025. Se incluye un Exhibit 99.1, Acuerdo de Presentaci贸n Conjunta.
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. 氚� Steven A. Cohen鞚� 2025雲� 8鞗� 4鞚� 旮办鞙茧 Avalo Therapeutics, Inc.(AVTX)鞚� 588,632欤�鞐� 雽�頃� 靾橂彊鞝� 靻岇湢甓岇潉 瓿店皽頃橂姅 Schedule 13G毳� 瓿惦彊 鞝滌稖頄堨姷雼堧嫟. 鞚� 歆�攵勳潃 須岇偓鞚� 氤错喌欤� 氚滍枆 欤检嫕鞚� 5.4%鞐� 頃措嫻頃橂┌, Exchange Act 靹轨厴 13(d)鞐� 霐半ジ 鞁れ 靻岇湢甓� 瓿店皽 旮办鞚� 於╈”頃╇媹雼�.
欤检嫕鞚� Point72 Asset Management臧� 甏�毽晿電� 韴瀽 韼�霌滌澑 Point72 Associates臧� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 靹� 氤搓碃鞛愲姅 氇憪 鞚橁舶甓� 氚� 觳橂秳甓岇潉 瓿奠湢頃橂┌, 雼弲 甓岉暅鞚� 欤检灔頃橃 鞎婌姷雼堧嫟. 鞝滌稖靹滌棎電� 鞚� 歆�攵勳澊 Avalo鞚� 歆�氚瓣秾鞐� 鞓來枼鞚� 氙胳箻霠る姅 鞚橂弰臧� 鞐嗢溂氅�, 靾橂彊鞝� 韴瀽(攴滌箼 13d-1(c))搿� 攵勲霅滊嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 靹滊獏鞚� 2025雲� 8鞗� 5鞚� 甓岉暅 鞛堧姅 Jason M. Colombo臧� 靾橅枆頄堨姷雼堧嫟. Exhibit 99.1 瓿惦彊 鞝滌稖 瓿勳暯靹滉皜 韽暔霅橃柎 鞛堨姷雼堧嫟.
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. et Steven A. Cohen ont conjointement d茅pos茅 un Schedule 13G divulguant une propri茅t茅 passive de 588 632 actions d鈥橝valo Therapeutics, Inc. (AVTX) au 4 ao没t 2025. Cette position repr茅sente 5,4 % du capital social ordinaire en circulation, atteignant le seuil qui exige la divulgation de la propri茅t茅 b茅n茅ficiaire en vertu de la Section 13(d) de l鈥橢xchange Act.
Les actions sont d茅tenues par Point72 Associates, un fonds d鈥檌nvestissement g茅r茅 par Point72 Asset Management. Les trois d茅clarants partagent le pouvoir de vote et de disposition ; aucun ne revendique une autorit茅 exclusive. Le d茅p么t indique que la participation n鈥檃 pas pour but d鈥檌nfluencer le contr么le d鈥橝valo et est class茅e comme un investissement passif (R猫gle 13d-1(c)). Les signatures ont 茅t茅 appos茅es par la personne autoris茅e Jason M. Colombo le 5 ao没t 2025. Un Exhibit 99.1 Accord de D茅p么t Conjoint est inclus.
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. und Steven A. Cohen haben gemeinsam ein Schedule 13G eingereicht, das den passiven Besitz von 588.632 Aktien von Avalo Therapeutics, Inc. (AVTX) zum 4. August 2025 offenlegt. Die Position entspricht 5,4 % des ausstehenden Stammkapitals des Unternehmens und erf眉llt damit die Schwelle f眉r die Offenlegung der wirtschaftlichen Eigent眉merschaft gem盲脽 Abschnitt 13(d) des Exchange Act.
Die Aktien werden von Point72 Associates gehalten, einem von Point72 Asset Management verwalteten Investmentfonds. Alle drei meldenden Personen teilen sich das Stimm- und Verf眉gungsrecht; keiner beansprucht Alleinbefugnis. Die Einreichung gibt an, dass die Beteiligung nicht darauf abzielt, die Kontrolle 眉ber Avalo zu beeinflussen, und als passives Investment (Regel 13d-1(c)) klassifiziert ist. Die Unterschriften wurden am 5. August 2025 von der bevollm盲chtigten Person Jason M. Colombo geleistet. Eine Anlage 99.1 Gemeinsame Einreichungsvereinbarung ist beigef眉gt.
- Point72, a respected institutional investor, accumulated 5.4 % of AVTX shares, potentially enhancing market confidence and liquidity.
- None.
Insights
TL;DR: Point72鈥檚 5.4 % passive stake signals institutional interest, modestly bullish for AVTX sentiment; no control intent disclosed.
Impact assessment: The entrance of a high-profile hedge fund adds credibility and potential liquidity to AVTX鈥檚 thinly traded shares. While 5.4 % is below activist thresholds, Point72鈥檚 research-driven approach often precedes additional accumulation if catalysts materialize. The passive 13G (vs. 13D) reduces governance pressure but still implies confidence in Avalo鈥檚 pipeline or valuation. The holding is concentrated鈥攕hared voting/dispositive power鈥攕o any future exit could create volatility. Overall, the filing is moderately positive and impactful for near-term market perception.
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. e Steven A. Cohen hanno presentato congiuntamente un Schedule 13G, rivelando una partecipazione passiva di 588.632 azioni di Avalo Therapeutics, Inc. (AVTX) al 4 agosto 2025. La posizione rappresenta il 5,4% del capitale sociale ordinario in circolazione, superando la soglia che richiede la divulgazione del possesso effettivo ai sensi della Sezione 13(d) dell'Exchange Act.
Le azioni sono detenute da Point72 Associates, un fondo di investimento gestito da Point72 Asset Management. Tutti e tre i soggetti segnalanti condividono il potere di voto e dispositivi; nessuno rivendica autorit脿 esclusiva. La dichiarazione afferma che la partecipazione non 猫 destinata a influenzare il controllo di Avalo ed 猫 classificata come investimento passivo (Regola 13d-1(c)). Le firme sono state apposte dall'autorizzato Jason M. Colombo il 5 agosto 2025. 脠 incluso un Exhibit 99.1, Accordo di Deposito Congiunto.
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. y Steven A. Cohen presentaron conjuntamente un Schedule 13G revelando una propiedad pasiva de 588,632 acciones de Avalo Therapeutics, Inc. (AVTX) al 4 de agosto de 2025. La posici贸n representa el 5.4 % del capital social com煤n en circulaci贸n, cumpliendo con el umbral que exige la divulgaci贸n de propiedad beneficiaria bajo la Secci贸n 13(d) de la Exchange Act.
Las acciones son mantenidas por Point72 Associates, un fondo de inversi贸n gestionado por Point72 Asset Management. Las tres personas que reportan comparten el poder de voto y dispositivos; ninguna reclama autoridad exclusiva. La presentaci贸n indica que la participaci贸n no est谩 destinada a influir en el control de Avalo y se clasifica como una inversi贸n pasiva (Regla 13d-1(c)). Las firmas fueron ejecutadas por la persona autorizada Jason M. Colombo el 5 de agosto de 2025. Se incluye un Exhibit 99.1, Acuerdo de Presentaci贸n Conjunta.
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. 氚� Steven A. Cohen鞚� 2025雲� 8鞗� 4鞚� 旮办鞙茧 Avalo Therapeutics, Inc.(AVTX)鞚� 588,632欤�鞐� 雽�頃� 靾橂彊鞝� 靻岇湢甓岇潉 瓿店皽頃橂姅 Schedule 13G毳� 瓿惦彊 鞝滌稖頄堨姷雼堧嫟. 鞚� 歆�攵勳潃 須岇偓鞚� 氤错喌欤� 氚滍枆 欤检嫕鞚� 5.4%鞐� 頃措嫻頃橂┌, Exchange Act 靹轨厴 13(d)鞐� 霐半ジ 鞁れ 靻岇湢甓� 瓿店皽 旮办鞚� 於╈”頃╇媹雼�.
欤检嫕鞚� Point72 Asset Management臧� 甏�毽晿電� 韴瀽 韼�霌滌澑 Point72 Associates臧� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 靹� 氤搓碃鞛愲姅 氇憪 鞚橁舶甓� 氚� 觳橂秳甓岇潉 瓿奠湢頃橂┌, 雼弲 甓岉暅鞚� 欤检灔頃橃 鞎婌姷雼堧嫟. 鞝滌稖靹滌棎電� 鞚� 歆�攵勳澊 Avalo鞚� 歆�氚瓣秾鞐� 鞓來枼鞚� 氙胳箻霠る姅 鞚橂弰臧� 鞐嗢溂氅�, 靾橂彊鞝� 韴瀽(攴滌箼 13d-1(c))搿� 攵勲霅滊嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 靹滊獏鞚� 2025雲� 8鞗� 5鞚� 甓岉暅 鞛堧姅 Jason M. Colombo臧� 靾橅枆頄堨姷雼堧嫟. Exhibit 99.1 瓿惦彊 鞝滌稖 瓿勳暯靹滉皜 韽暔霅橃柎 鞛堨姷雼堧嫟.
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. et Steven A. Cohen ont conjointement d茅pos茅 un Schedule 13G divulguant une propri茅t茅 passive de 588 632 actions d鈥橝valo Therapeutics, Inc. (AVTX) au 4 ao没t 2025. Cette position repr茅sente 5,4 % du capital social ordinaire en circulation, atteignant le seuil qui exige la divulgation de la propri茅t茅 b茅n茅ficiaire en vertu de la Section 13(d) de l鈥橢xchange Act.
Les actions sont d茅tenues par Point72 Associates, un fonds d鈥檌nvestissement g茅r茅 par Point72 Asset Management. Les trois d茅clarants partagent le pouvoir de vote et de disposition ; aucun ne revendique une autorit茅 exclusive. Le d茅p么t indique que la participation n鈥檃 pas pour but d鈥檌nfluencer le contr么le d鈥橝valo et est class茅e comme un investissement passif (R猫gle 13d-1(c)). Les signatures ont 茅t茅 appos茅es par la personne autoris茅e Jason M. Colombo le 5 ao没t 2025. Un Exhibit 99.1 Accord de D茅p么t Conjoint est inclus.
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. und Steven A. Cohen haben gemeinsam ein Schedule 13G eingereicht, das den passiven Besitz von 588.632 Aktien von Avalo Therapeutics, Inc. (AVTX) zum 4. August 2025 offenlegt. Die Position entspricht 5,4 % des ausstehenden Stammkapitals des Unternehmens und erf眉llt damit die Schwelle f眉r die Offenlegung der wirtschaftlichen Eigent眉merschaft gem盲脽 Abschnitt 13(d) des Exchange Act.
Die Aktien werden von Point72 Associates gehalten, einem von Point72 Asset Management verwalteten Investmentfonds. Alle drei meldenden Personen teilen sich das Stimm- und Verf眉gungsrecht; keiner beansprucht Alleinbefugnis. Die Einreichung gibt an, dass die Beteiligung nicht darauf abzielt, die Kontrolle 眉ber Avalo zu beeinflussen, und als passives Investment (Regel 13d-1(c)) klassifiziert ist. Die Unterschriften wurden am 5. August 2025 von der bevollm盲chtigten Person Jason M. Colombo geleistet. Eine Anlage 99.1 Gemeinsame Einreichungsvereinbarung ist beigef眉gt.
FAQ
How many Avalo Therapeutics (AVTX) shares does Point72 own?
What percentage of AVTX does the 588,632-share stake represent?
Is Point72 seeking control of Avalo Therapeutics?
Who are the reporting persons on this Schedule 13G?
When was the beneficial-ownership date triggering the filing?
